Naftidrofuryl-driven regulation of endothelial ICAM-1 involves nitric oxide

Free Radical Biology and Medicine

Volumn 34, Issue 5, 2003, Pages 616-625

  Marconi, A ^a   Darquenne, S ^a   Boulmerka, A ^a   Mosnier, M ^b   D'Alessio, Patrizia ^a  

^a HÔPITAL PAUL BROUSSE   (France)

^b Merck Lipha   (France)

Author keywords

Endothelium; Free radicals; ICAM 1; Naftidrofuryl; Nitric oxide

Indexed keywords

INTERCELLULAR ADHESION MOLECULE 1; NAFTIDROFURYL; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE INHIBITOR; TUMOR NECROSIS FACTOR;

ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; ENDOTHELIUM CELL; ENZYME SUBUNIT; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; STRESS FIBER; THROMBOCYTE AGGREGATION INHIBITION; UMBILICAL VEIN; VASOSPASM;

EID: 0037371818     PISSN: 08915849     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0891-5849(02)01368-0     Document Type: Article

References (47)

1. Serafeim A., Gordon J. The immune system gets nervous. Curr. Opin. Pharmacol. 1:2001;398-403.
2. Martin G.R. Vascular receptors for 5-hydroxytriptamine distribution, function, and classification . Pharmacol. Ther. 62:1994;283-324.
3. Singhal A.B., Caviness V.S., Begleiter A.F., Mark E.J., Rordorf G., Koroshetz W.J. Cerebral vasoconstriction and stroke after use of serotoninergic drugs. Neurology. 58:2002;130-133.
4. Drouet L., Bal Dit Sollier C., Ruton S., Pignaud G. Role of serotonin in arteriolar thrombosis and secondary vasospasm. J. Cardiovasc. Pharmacol. 16:1990;49-53.
5. Kirsten R., Erdeg B., Moxter D., Hesse K., Breidert M., Nelson K. Platelet aggregation after naftidrofuryl application in vitro and ex vivo. Int. J. Clin. Pharmacol. Ther. 33:1995;81-84.
6. Abbot F.V., Hong Y., Blier P. Activation of 5-HT2A receptors potentiates pain produced by inflammatory mediators. Neuropharmacology. 35:1996;99-110.
7. Endemann D., Schweda F., Stubanus M., Ittner K.P., Fischereder M., Kammerl M.C., Kramer B.K. Naftidrofuryl exerts antiserotoninergic but no endothelin-receptor blocking effects in AS4.1 cells, juxtaglomerular cells, and isolated perfused rat kidneys. J. Cardiovasc. Pharmacol. 39:2002;1-8.
8. Hermann K.S., Kreuzer H. Effect of serotoninergic antagonism on local responses to an acute and selective endothelial trauma in vivo. J. Cardiovasc. Pharmacol. 16:1990;40-44.
9. Miyake K., Takagi N., Takeo S. Effects of naftidrofuryl oxalate on microsphere embolism-induced decrease in regional blood flow of rat brain. Br. J. Pharmacol. 112:1994;226-230.
10. Wiensperger N.F. Serotonin, 5-HT2 receptors, and their blockade by naftidrofuryl a targeted therapy of vascular diseases . J. Cardiovasc. Pharmacol. 23:1994;37-43.
11. Michiels C., Arnould T., Janssens D., Alexandre I., Houbion A., Remacle J. Effects of naftidrofuryl on hypoxia-induced activation and mortality of human endothelial cells. J. Pharmacol. Exp. Ther. 267:1993;904-911.
12. Leterrier J.F., Maher A., Eyer J., Gou J.P., Haddad K., Pouplard-Berthelaix A. Naftidrofuryl, a putative activator of neuron survival, stimulates the expression of neurofilament heavy subunit in cultivated spinal cords neurons from chicken. Biochem. Biophys. Res. Commun. 200:1994;504-512.
13. Emeriau J.P., Lehert P., Mosnier M. Efficacy of naftidrofuryl in patients with vascular or mixed dementia results of a multicenter, double-blind trial . Clin. Ther. 22:2000;834-844.
14. Huang E.P. Synaptic plasticity a role for nitric oxide in LTP . Curr. Biol. 7:1997;141-143.
15. Liew F.Y. Regulation of lymphocyte functions by nitric oxide. Curr. Opin. Immunol. 7:1995;396-399.
16. Stamler J.S., Loscalzo J. Biochemistry of nitric oxide and its redox-activated forms. Science. 258:1992;1898-1902.
17. Mendelsohn M.E., O'Neil S., George D., Loscalzo J. Inhibition of fibrinogen binding to human platelets by S-nitroso-N-acetylcystein. J. Biol. Chem. 265:1990;19028-19034.
18. Moellering D., Mc Andrews G., Patel R.P., Forman H.J., Mulcahy R.T., Jo H., Darley-Usmar V.M. The induction of GSH synthesis by nanomolar concentrations of NO in endothelial cells a role for γ-glutamyl cysteine synthetase and γ-glutamyl transpeptidase . FEBS Lett. 448:1999;292-296.
19. Drexler H., Zeiher A.M., Meinzer K., Just H. Correction of endothelial dysfunction in coronary microcirculation of hypercholesterolemic patients by L-arginine. Lancet. 338:1991;1546-1550.
20. Böger R.H., Bode-Böger S.M., Mügge A., Kienke S., Brandes R. Supplementation of hypercholesterolemic rabbits with L-arginine reduces the vascular release of superoxide anions and restores NO production. Atherosclerosis. 117:1995;273-284.
21. De Caterina R., Libby P., Peng H.B., Thannickal V.G., Rajavashisth T.B., Gimbrone M.A., Shin W.S., Liao J.K. Nitric oxide decreases cytokine-induced endothelial activation. J. Clin. Invest. 96:1995;60-68.
22. Orpana A., Rant V., Mikkola T., Viinikka L., Ylikorkala O. Inducible nitric oxide and prostacyclin productions are differently controlled by extracellular matrix and cell density in HUVEC. J. Cell Biochem. 64:1997;538-546.
23. Kubes P., Suzuki M., Granger D.N. Nitric oxide an endogenous modulator of leukocyte adhesion . Proc. Natl. Acad. Sci. USA. 88:1991;4651-4655.
24. Biffl W.L., Moore E.E., Moore F.A., Barnett C. NO reduces endothelial expression of ICAM-1/CD54. J. Surg. Res. 63:1996;328-332.
25. Zadeh M.S., Kolb J.P., Geromin D., D'Anna R., Boulmerka A., Marconi A., Dugas B., Marsac C., D'Alessio P. Regulation of ICAM-1/CD54 expression on human endothelial cells by hydrogen peroxide involves inducible NO synthase. J. Leukoc. Biol. 67:2000;327-334.
26. Carlos T.M., Harlan J.M. Leukocyte endothelium adhesion molecules. Blood. 84:1994;2068-2101.
27. Carpen O., Pallai P., Stauton D.E., Springer T.A. Association of intercellular adhesion molecule-1 (ICAM-1) with actin-containing cytoskeleton α-actinin. J. Cell Biol. 5:1992;1223-1234.
28. Helander T.S., Carpen O., Turunen O., Kovanen P.E., Vaheri A., Timonen T. ICAM-2 redistributed by ezrin as a target for killer cells. Nature. 382:1996;265-268.
29. Thorp K.M., Southern C., Bird I.N., Matthews N. Tumour necrosis factor induction of ELAM-1 and ICAM-1 on human umbilical vein endothelial cells analysis of tumour necrosis factor-receptor interactions . Cytokine. 4:1992;313-319.
30. 2 and TNF-α activate ICAM-1/CD54 gene transcription through distinct cis-regulatory elements within the ICAM-1/CD54 promoter. J. Biol. Chem. 270:1995;18966-18974.
31. Goligorsky M.S., Abedi H., Noiri E., Takhtajan A., Lense S., Romanov V., Zachary I. Nitric oxide modulation of focal adhesions in endothelial cells. Am. J. Physiol. 276:1999;1271-1281.
32. Zampolli A., Basta G., Lazzerini G., Feelisch M., De Caterina R. Inhibition of endothelial cell activation by nitric oxide donors. J. Pharmacol. Exp. Ther. 295:2000;818-823.
33. Levy L.L., Wallace J.D. Cerebral blood flow regulation. II. Vasodilator mechanisms. Stroke. 8:1977;189-193.
34. Fontaine L., Grand M., Chabert J., Szarvasi E., Bayssat M. Pharmacologie gnrale d'une substance nouvelle vasodilatatrice le naftidrofuryl . Bull. Chim. Ther. 6:1968;463-469.
35. Admani A.K. New approach to treatment of recent stroke. Br. Med. J. 2:1978;1678-1679.
36. Meehan S.E., Preece P.E., Walker W.F. The usefulness of naftidrofuryl in severe peripheral ischemia a symptomatic assessment using linear analogue scales . Angiology. 33:1982;625-634.
37. Trubestein G., Bohme H., Heidrich H., Heinrich F., Hirche H., Maass U., Morl H., Rudofsky G. Naftidrofuryl in chronic arterial disease. Results of a controlled multicenter study. Angiology. 35:1984;701-708.
38. Lehert P., Riphagen F.E., Gamand S. The effect of naftidrofuryl on intermittent claudication a meta-analysis . J. Cardiovasc. Pharmacol. 16:1990;81-86.
39. Branconnier R.J., Cole J.O. The impairment index as a symptom-independent parameter of drug efficacy in geriatric psychopharmacology. J. Gerontol. 33:1978;217-223.
40. Maloteaux J.M., Haiech J., De Campeneere D., Berta P., Vidal N. Biochemical and physiological evidences for antiserotonergic properties of naftidrofuryl. Arzneimittelforschung. 36:1986;1194-1198.
41. Zander J.F., Aarhus L.L., Katusic Z.S., Rubanyi G.M., Vanhoutte P.M. Effects of naftidrofuryl on adrenergic nerves, endothelium, and smooth muscle in isolated canine blood vessels. J. Pharmacol. Exp. Ther. 239:1986;760-767.
42. Verheggen R., Schror K. Effects of naftidrofuryl on platelet-induced vasospasm in vitro. Role of antiserotonergic actions. Arzneimittelforschung. 43:1993;330-334.
43. Barradas M.A., Jagroop I.A., Mikhailidis D.P. Naftidrofuryl inhibits the release of 5-hydroxytryptamine and platelet-derived growth factor from human platelets. Clin. Chim. Acta. 230:1994;157-167.
44. Schulze-Osthoff K., Bakker A.C., Vanhaesebroek B., Beyaert R., Jacob W.A., Fiers W. Cytotoxic activity of tumor necrosis factor is mediated by early damage of mitochondrial function. J. Biol. Chem. 267:1992;226-234.
45. Pires J.G., Ramage A.G., Jacobs M. ICI 169,369, a 5-HT2/5-HT1C antagonist that can evoke endothelium-dependent relaxation in rabbit aorta. J. Auton. Pharmacol. 13:1993;249-255.
46. Egashira K. Clinical importance of endothelial function in arteriosclerosis and ischemic heart disease. Circ. J. 66:2002;529-533.
47. Gewaltig M.T., Kojda G. Vasoprotection by nitric oxide mechanisms and therapeutical potential . Cardiovasc. Res. 55:2002;250-260.